UCB SA (OTCMKTS:UCBJY) Short Interest Update

UCB SA (OTCMKTS:UCBJY) saw a significant decrease in short interest during the month of November. As of November 15th, there was short interest totalling 800 shares, a decrease of 73.3% from the October 31st total of 3,000 shares. Based on an average trading volume of 58,500 shares, the short-interest ratio is presently 0.0 days.

UCB Stock Performance

OTCMKTS UCBJY traded down $1.08 on Wednesday, hitting $95.37. The stock had a trading volume of 6,813 shares, compared to its average volume of 21,580. UCB has a 52-week low of $36.70 and a 52-week high of $99.40. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. The business’s fifty day moving average price is $93.54 and its 200 day moving average price is $84.04.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.